Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVI-MSC for Post COVID-19 Pulmonary Compromise
NCT04992247Phase 2Withdrawn
- Sponsor
- Sorrento Therapeutics
- Start
- Feb 2024
- Primary completion
- Jul 2024
- Modality
- Stem Cell Therapies
01
Overview
A Phase 2 trial of COVI-MSC in post acute COVID-19 syndrome, sponsored by Sorrento Therapeutics. Planned start Feb 2024; status: withdrawn.
02
Drugs
COVI-MSC
03
Conditions
post acute COVID-19 syndrome
Beyond the preview
Go deeper on NCT04992247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04992247.